Stockreport

Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide...

Hoth Therapeutics, Inc.  (HOTH) 
PDF NEW YORK April 13, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) , a clinical-stage biopharmaceutical company, today announced positive data from its HT-V [Read more]